Nanjing Zenkom Pharmaceutical Co., Ltd.

The main purpose of the study is to evaluate the pharmacokinetic characteristics of the test preparation of pilocarpine hydrochloride eye drops and the reference preparation of pilocarpine hydrochloride eye drops (Vuity). The secondary purpose of the study is to investigate the safety of the test preparation and the reference preparation after administration to the subjects.

Main purpose: To use Chinese healthy subjects as the test subjects, adopt a self-crossover design, determine the blood concentration of ruxolitinib in plasma after administration of ruxolitinib phosphate tablets produced by Nanjing Zhengke Pharmaceutical Co., Ltd. over time, estimate the corresponding pharmacokinetic parameters, and use ruxolitinib phosphate tablets [trade name: Jakavi®, specification: 5mg (based on ruxolitinib)] produced by Novartis Pharma Schweiz AG and Novartis Pharma Stein AG as a reference to evaluate the bioequivalence between the preparations. Secondary purpose: To observe the safety of ruxolitinib phosphate tablets in Chinese healthy subjects.

The main purpose of the study is to investigate the relative bioavailability of the test preparation Vonoprazan fumarate tablets (specification: 20 mg, produced by Nanjing Zhengke Pharmaceutical Co., Ltd.) and the reference preparation Vonoprazan fumarate tablets (Walker?, specification: 20 mg, licensed by Takeda Pharmaceutical Company Limited) after a single oral dose after a meal in healthy adult subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. Secondary purpose of the study: To evaluate the safety of the test preparation and the reference preparation after a single oral dose after a meal in healthy adult subjects in China.